Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the treatment effect of panitumumab plus FOLFIRI on overall survival (OS) and progression-free survival (PFS) compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer (mCRC) among subjects with wild-type KRAS tumors and mutant KRAS tumors.
Critère d'inclusion
- Patients with Previously Treated Metastatic Colorectal Cancer